Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received.  Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the Vienna University of Technology and the Maria ... perfect semiconductor crystals into a silicon nanowire. With ... fast and multi-functional processing units can be accommodated ... research results will be published in the journal ... the cornerstone of future chip technology, but the ...
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Last year, ... Systems , a leading global provider of data management ... with TrialMaster, a leading-edge system for electronic data capture ... of universal design and study execution tools added TrialMaster ... and much anticipated version of Transform for TrialMaster, is ...
(Date:7/23/2014)... 23 de julio de 2014 ADB ... Compañía) ha anunciado hoy una asociación con Austen ... (ABIA o el Instituto), para el propósito de ... de terapia de señal bioeléctrica (el E-QURE BST ... Instituto, que tiene una importante experiencia en cicatrización ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6
... CITY, Calif. , June 17 OncoMed Pharmaceuticals, Inc. ... global strategic alliance to discover, develop and commercialize novel anti-cancer stem ... a subset of tumor cells believed to play a significant role ... , , ...
... Institute have developed a new, ultra-simple method for ... of a meter thick. The process, which requires ... surface including silicon wafers, could have important implications ... assistant professor in the Department of Physics, Applied ...
... MD ... the functional relevance of a drug treatment on the heart following direct coronary flow ... ... MD Biosciences , a Preclinical Contract Research Organization (CRO), offers in vivo models for ...
Cached Biology Technology:OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5Researchers develop ultra-simple method for creating nanoscale gold coatings 2MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury 2
(Date:7/23/2014)... , , , , ... , , , , ... healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost entirely ...
(Date:7/23/2014)... Washington, DC -- The planet,s soil releases about 60 ... which is far more than that released by burning ... respiration. This enormous release of carbon is balanced by ... and other plant matter, as well as by the ... studies have documented that rising temperatures increase the rate ...
(Date:7/23/2014)... , July 23, 2014 BioCatch, ... detection, announced today it has been named in Gartner,s ... Market Guide replaces Gartner,s well-known Magic Quadrant for Web ... BioCatch as one of several vendors to deliver passive ... will become a standard feature of at least 30% ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Climate change and the soil 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... whole new interface between nanotechnology and neuroscience, scientists ... to detect, stimulate, and inhibit nerve signals along ... , Harvard chemist Charles M. Lieber and colleagues ... this week in the journal Science. , "We ...
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... Medical Research have discovered a mechanistic link between cellular ... proteins that lead to nerve cell injury and death ... , That link is Protein Disulphide Isomerase ... protein folding in times of cellular stress. Published ...
Cached Biology News:Nanowire arrays can detect signals along individual neurons 2New lab technique churns out fungus' potential cancer fighter 2Key stress protein linked to toxicities responsible for Parkinson's, Alzheimer's 2
...
... ISOQUANT(R) Isoaspartate Detection Kit is intended for ... proteins and peptides, which can result from ... rearrangement of aspartic acid residues during storage ... depend on the monitoring of charge differences ...
...
...
Biology Products: